200 related articles for article (PubMed ID: 22127819)
1. A review of risk measures in pharmacoepidemiology with tips for statisticians in the pharmaceutical industry.
Quartey G; Wang J; Kim J
Pharm Stat; 2011; 10(6):548-53. PubMed ID: 22127819
[TBL] [Abstract][Full Text] [Related]
2. Estimating post-marketing exposure to pharmaceutical products using ex-factory distribution data.
Telfair T; Mohan AK; Shahani S; Klincewicz S; Atsma WJ; Thomas A; Fife D
Pharmacoepidemiol Drug Saf; 2006 Oct; 15(10):749-53. PubMed ID: 16758501
[TBL] [Abstract][Full Text] [Related]
3. Propensity score methods in drug safety studies: practice, strengths and limitations.
Wang J; Donnan PT
Pharmacoepidemiol Drug Saf; 2001; 10(4):341-4. PubMed ID: 11760497
[No Abstract] [Full Text] [Related]
4. The role of databases in drug postmarketing surveillance.
Rodriguez EM; Staffa JA; Graham DJ
Pharmacoepidemiol Drug Saf; 2001; 10(5):407-10. PubMed ID: 11802586
[TBL] [Abstract][Full Text] [Related]
5. Pharmacoenvironmentology--a component of pharmacovigilance.
Rahman SZ; Khan RA; Gupta V; Uddin M
Environ Health; 2007 Jul; 6():20. PubMed ID: 17650313
[TBL] [Abstract][Full Text] [Related]
6. Pharmacoepidemiology in the postmarketing assessment of the safety and efficacy of drugs in older adults.
Hilmer SN; Gnjidic D; Abernethy DR
J Gerontol A Biol Sci Med Sci; 2012 Feb; 67(2):181-8. PubMed ID: 21653991
[TBL] [Abstract][Full Text] [Related]
7. Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership.
Ryan PB; Madigan D; Stang PE; Overhage JM; Racoosin JA; Hartzema AG
Stat Med; 2012 Dec; 31(30):4401-15. PubMed ID: 23015364
[TBL] [Abstract][Full Text] [Related]
8. The role of pharmacoepidemiology research in postmarketing surveillance and anesthesia practice/critical care medicine.
Grasela TH; Watkins WD; Hug CC; McLeskey CH; Nahrwold ML; Roizen MF; Stanley TH; Thisted RA; Walawander CA; White PF
Anesth Analg; 1993 Oct; 77(4 Suppl):S44-50. PubMed ID: 8214697
[TBL] [Abstract][Full Text] [Related]
9. [Organization and results of drug vigilance in France].
Bégaud B; Chaslerie A; Haramburu F
Rev Epidemiol Sante Publique; 1994; 42(5):416-23. PubMed ID: 7973001
[TBL] [Abstract][Full Text] [Related]
10. European pharmacovigilance: an overview of pharmacovigilance inspections.
Koster MC; van den Oetelaar AH
Pharmacoepidemiol Drug Saf; 2005 Oct; 14(10):711-3. PubMed ID: 16142691
[No Abstract] [Full Text] [Related]
11. [Study on method on post-marketing traditonal Chinese medicine safety assessment].
Kou Q; Zhao S; Feng G; Xie Y
Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2771-5. PubMed ID: 22292361
[TBL] [Abstract][Full Text] [Related]
12. European pharmacovigilance legislation: has it led to implementation of pharmacovigilance inspections?
Bleumink GS; in't Veld BA; Stricker BH
Pharmacoepidemiol Drug Saf; 2001; 10(4):339-40. PubMed ID: 11760496
[No Abstract] [Full Text] [Related]
13. The US drug safety system: role of the pharmaceutical industry.
Gibson BR; Suh R; Tilson H
Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):110-4. PubMed ID: 17724741
[TBL] [Abstract][Full Text] [Related]
14. The withdrawal of rofecoxib.
Arellano FM
Pharmacoepidemiol Drug Saf; 2005 Mar; 14(3):213-7. PubMed ID: 15724267
[No Abstract] [Full Text] [Related]
15. Pharmacovigilance during the pre-approval phases: an evolving pharmaceutical industry model in response to ICH E2E, CIOMS VI, FDA and EMEA/CHMP risk-management guidelines.
Hartford CG; Petchel KS; Mickail H; Perez-Gutthann S; McHale M; Grana JM; Marquez P
Drug Saf; 2006; 29(8):657-73. PubMed ID: 16872240
[TBL] [Abstract][Full Text] [Related]
16. [Proposal of guidelines for the set-up of pharmaco-epidemiologic studies in drug surveillance].
de Tricornot B; Saddier P; Bons B; Clément JP; Courtand M; Lamarque V; Thomas A; Tomczyk S; Vaissère J
Therapie; 1997; 52(6):579-85. PubMed ID: 9734111
[TBL] [Abstract][Full Text] [Related]
17. European commission consultation on pharmacovigilance.
Waller P; Beard K; Egberts T; Evans S; Hallas J; Hasford J; Laporte JR; Moore N; Shakir S; Sturkenboom M
Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):108-9. PubMed ID: 18058839
[No Abstract] [Full Text] [Related]
18. Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999.
Cross J; Lee H; Westelinck A; Nelson J; Grudzinskas C; Peck C
Pharmacoepidemiol Drug Saf; 2002 Sep; 11(6):439-46. PubMed ID: 12426927
[TBL] [Abstract][Full Text] [Related]
19. Who is now responsible for discovering and warning about adverse effects of generic drugs?
Kesselheim AS; Green MD; Avorn J
JAMA; 2013 Sep; 310(10):1023-4. PubMed ID: 23922000
[No Abstract] [Full Text] [Related]
20. Statistical aspects in comparative benefit-risk assessment: challenges and opportunities for pharmaceutical statisticians.
Quartey G; Wang J
Pharm Stat; 2012; 11(1):82-5. PubMed ID: 21997832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
